Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-BC8 Antibody Conditioning for Advanced AML/MDS
NCT00119366Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2003
- Primary completion
- Aug 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of apamistamab in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Started May 2003; status: terminated.
02
Drugs
apamistamab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00119366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00119366.